Lorlatinib - PF-06463922

Pfizer

Status

Treatments: Drug: Lorlatinib

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03127618

B746

Details and patient eligibility

About

Lorlatinib expanded access program

Sex

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult, Senior

Exclusion criteria